Robert W. Baird analyst Catherine Schulte reiterated a Buy rating on Bio-Techne Corporation (NASDAQ: TECH) yesterday and set a price target of $191. The company’s shares closed yesterday at $180.14, close to its 52-week high of $183.90.
According to TipRanks.com, Schulte is a 5-star analyst with an average return of 26.3% and a 76.3% success rate. Schulte covers the Healthcare sector, focusing on stocks such as Oxford Immunotec, NanoString Tech, and Exact Sciences.
Bio-Techne Corporation has an analyst consensus of Moderate Buy, with a price target consensus of $180.33.
See today’s analyst top recommended stocks >>
Based on Bio-Techne Corporation’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $40.9 million. In comparison, last year the company had a net profit of $28.81 million.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through three segments include: Biotechnology, Protein Platforms, and Diagnostics Divisions.
